Lei Liu, Xiaobo Li, Zhiqiang Lin, Yongzhi Xie, Shunxiang Huang, Huadong Zhao, Beisha Tang, Ruxu Zhang
Health Management Center, Third Xiangya Hospital, Central South University, Changsha, China.
Department of Neurology, Third Xiangya Hospital, Central South University, Changsha, China.
Eur J Neurol. 2023 Apr;30(4):1069-1079. doi: 10.1111/ene.15700. Epub 2023 Feb 5.
The aim was to characterize the phenotypic and genotypic features of myelin protein zero (MPZ) related neuropathy and provide baseline data for longitudinal natural history studies or drug clinical trials.
Clinical, neurophysiological and genetic data of 37 neuropathy patients with MPZ mutations were retrospectively collected.
Nineteen different MPZ mutations in 23 unrelated neuropathy families were detected, and the frequency of MPZ mutations was 5.84% in total. Mutations c.103_104InsTGGTTTACACCG, c.513dupG, c.521_557del and c.696_699delCAGT had not been reported previously. Hot spot mutation p.Thr124Met was detected in four unrelated families, and seven patients carried de novo mutations. The onset age indicated a bimodal distribution: prominent clustering in the first and fourth decades. The infantile-onset group included 12 families, the childhood-onset group consisted of two families and the adult-onset group included nine families. The Charcot-Marie-Tooth Disease Neuropathy Score ranged from 3 to 25 with a mean value of 15.85 ± 5.88. Mutations that changed the cysteine residue (p.Arg98Cys, p.Cys127Trp, p.Ser140Cys and p.Cys127Arg) in the extracellular region were more likely to cause severe early-onset Charcot-Marie-Tooth disease type 1B (CMT1B) or Dejerine-Sottas syndrome. Nonsense-mediated mRNA decay mutations p.Asp35delInsVVYTD, p.Leu174Argfs66 and p.Leu172Alafs63 were related to severe infantile-onset CMT1B or Dejerine-Sottas syndrome; however, mutation p.Val232Valfs*19 was associated with a relatively milder childhood-onset CMT1 phenotype.
Four novel MPZ mutations are reported that expand the genetic spectrum. De novo mutations accounted for 30.4% and were most related to a severe infantile-onset phenotype. Genetic and clinical data from this cohort will provide the baseline data necessary for clinical trials and natural history studies.
旨在描述髓磷脂蛋白零(MPZ)相关神经病变的表型和基因型特征,并为纵向自然史研究或药物临床试验提供基线数据。
回顾性收集37例患有MPZ突变的神经病变患者的临床、神经生理学和遗传学数据。
在23个无亲缘关系的神经病变家族中检测到19种不同的MPZ突变,MPZ突变的总频率为5.84%。c.103_104InsTGGTTTACACCG、c.513dupG、c.521_557del和c.696_699delCAGT突变此前未见报道。热点突变p.Thr124Met在4个无亲缘关系的家族中被检测到,7例患者携带新发突变。发病年龄呈双峰分布:在第一和第四个十年显著聚集。婴儿期发病组包括12个家族,儿童期发病组由2个家族组成,成人期发病组包括9个家族。夏科-马里-图斯病神经病变评分范围为3至25,平均值为15.85±5.88。改变细胞外区域半胱氨酸残基(p.Arg98Cys、p.Cys127Trp、p.Ser140Cys和p.Cys127Arg)的突变更有可能导致严重的早发性1B型夏科-马里-图斯病(CMT1B)或德热里纳-索塔斯综合征。无义介导的mRNA降解突变p.Asp35delInsVVYTD、p.Leu174Argfs66和p.Leu172Alafs63与严重的婴儿期发病CMT1B或德热里纳-索塔斯综合征相关;然而,突变p.Val232Valfs*19与相对较轻的儿童期发病CMT1表型相关。
报告了4种新的MPZ突变,扩展了遗传谱。新发突变占30.4%,且大多与严重的婴儿期发病表型相关。该队列的遗传和临床数据将为临床试验和自然史研究提供必要的基线数据。